DGIdb - METHOTREXATE Drug Record

METHOTREXATE chembl:CHEMBL34259 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MAXTREX
RASUVO
EMTEXATE PF
METOJECT
R-METHOTREXATE
MEXATE-AQ
ABITREXATE
R-9985
METHYLAMINOPTERIN
NSC-740
OTREXUP PFS
TCMDC-125488
TCMDC-123832
AMETHOPTERIN
EMT-25299
RHEUMATREX
OTREXUP
TCMDC-125858
EMTEXATE HIGH-POT
MEXATE
EBETREX
METHOTREXATE
TREXALL
ZLATAL
FOLEX
CL-14377
METOTREXATO
RASUVO®
MTX
ABITREXATE®
4-AMINO-10-METHYLFOLIC ACID
N-[4-[[(2,4-DIAMINO-6-PTERIDINYL)METHYL]METHYLAMINO]BENZOYL]-L-GLUTAMIC ACID
METHOTREXATUM
4-AMINO-N(10)-METHYLPTEROYLGLUTAMIC ACID
METHOTREXAT
MÉTHOTREXATE
chemidplus:59-05-2
chembl:CHEMBL34259
pubchem.compound:126941
drugbank:00563
rxcui:6851

Drug Info:

Drug Categories	toxic actions
Drug Categories	therapeutic uses
Drug Categories	reproductive control agents
Drug Categories	pterins
Drug Categories	pteridines
Drug Categories	pigments, biological
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	p-glycoprotein/abcb1 substrates
Drug Categories	oatp1b1/slco1b1 substrates
Drug Categories	oat3 substrates
Drug Categories	nucleic acid synthesis inhibitors
Drug Categories	noxae
Drug Categories	myelosuppressive agents
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	immunosuppressive agents
Drug Categories	immunologic factors
Drug Categories	heterocyclic compounds, 2-ring
Drug Categories	heterocyclic compounds
Drug Categories	folic acid antagonists
Drug Categories	enzyme inhibitors
Drug Categories	dermatologic agents
Drug Categories	chemical actions and uses
Drug Categories	biological factors
Drug Categories	bcrp/abcg2 substrates
Drug Categories	antirheumatic agents
Drug Categories	antineoplastic and immunomodulating agents
Drug Categories	antineoplastic agents
Drug Categories	antimetabolites, antineoplastic
Drug Categories	antimetabolites
Drug Categories	aminopterin
Drug Categories	abortifacient agents, nonsteroidal
Drug Categories	abortifacient agents
Drug Groups	approved
Drug Type	small molecule
FDA Approval	approved
Drug Class	Small molecule
Drug Indications	DMARD
Drug Categories	photosensitizing agents
Drug Categories	p-glycoprotein substrates
Drug Categories	oatp1b3 substrates
Drug Categories	oat3/slc22a8 substrates
Drug Categories	oat3/slc22a8 inhibitors
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	nephrotoxic agents
Drug Categories	narrow therapeutic index drugs
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	hepatotoxic agents
Drug Categories	folic acid analogues
Drug Categories	drugs that are mainly renally excreted
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	dermatologicals
Drug Categories	cytochrome p-450 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	agents causing muscle toxicity

(9 More Sources)

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer
Allegra et al., 1985, Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates., Proc. Natl. Acad. Sci. U.S.A.
López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J
Kurzawski M et al., 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients., Pharmacogenomics
Lima A et al., 2016, Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome., Pharmacogenomics
Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
Muralidharan N et al., 2016, ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis., Pharmacogenomics
Salazar J et al., 2014, Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?, Pharmacogenomics
Iannaccone CK et al., 2011, Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study., Rheumatology (Oxford)
James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
Wessels JA et al., 2006, Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis., Arthritis Rheum
Dervieux T et al., 2004, Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis., Arthritis Rheum
Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet
Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood
Kodidela S et al., 2015, Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia., Eur J Clin Pharmacol
Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J
Salazar J et al., 2012, Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia., Pharmacogenomics J
Sharma S et al., 2009, Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians., Pharmacogenet Genomics
Al-Shakfa F et al., 2009, DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia., Clin Cancer Res
Ongaro A et al., 2009, Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival., Haematologica
Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry
Hänggi et al., 1976, Altered regulation of the rate of synthesis of dihydrofolate reductase in methotrexate-resistant hamster cells., J. Biol. Chem.
Wani et al., 1994, Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells., Cancer Res.
Kaufman et al., 1981, Amplification and loss of dihydrofolate reductase genes in a Chinese hamster ovary cell line., Mol. Cell. Biol.
Domin et al., 1983, Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy., Cancer Res.
Thompson et al., 1992, Assay for expression of methotrexate-resistant dihydrofolate reductase activity in the presence of drug-sensitive enzyme., J Pharmacol Toxicol Methods
Selassie et al., 1982, A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate., J. Med. Chem.
Cavalcanti et al., 1992, Simultaneous changes in various mechanisms that mediate the cell incorporation of folate compounds account for low levels of resistance to methotrexate., Cell Biochem. Funct.
Serra et al., 2004, Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells., Ann. Oncol.
Bennett et al., 2006, Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate., Proc. Natl. Acad. Sci. U.S.A.
Uga et al., 2006, A new mechanism of methotrexate action revealed by target screening with affinity beads., Mol. Pharmacol.
Al-Rashood et al., 2006, Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs., Bioorg. Med. Chem.
Totani et al., 2006, High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates., Bioorg. Med. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Assaraf, 2007, Molecular basis of antifolate resistance., Cancer Metastasis Rev.
Costea I et al., 2006, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia., Haematologica
Costea et al., 2003, The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia., Pharmacogenetics
Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood
Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
den Hoed MA et al., 2015, Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia., Pharmacogenomics J
Lopez-Lopez E et al., 2013, Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia., Pharmacogenet Genomics
Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer
Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet
Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.
Jekic B et al., 2013, Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients., Eur J Clin Pharmacol
Hayashi H et al., 2009, Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis., J Clin Pharm Ther
van der Straaten RJ et al., 2007, Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients., Pharmacogenomics
Garcia-Bournissen F et al., 2007, Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene., Leuk Res
Dervieux T et al., 2004, Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis., Pharmacogenetics
Cheng Q et al., 2004, A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells., Pharmacogenetics
Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids
Krajinovic M et al., 2005, Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis., Pharmacogenomics J
Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Ansari M et al., 2012, Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol
Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics
Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics
Huang L et al., 2008, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia., Leukemia
de Jonge R et al., 2005, Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia., Blood
Yanagimachi M et al., 2013, Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy., Int J Hematol
Simon N et al., 2013, Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy., Pharmacogenomics J
Ranganathan P et al., 2008, Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis., J Rheumatol
Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.
Chen Y et al., 2017, Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis., Pharmacogenomics
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
Pohl et al., 2003, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin., J. Clin. Oncol.
Foell et al., 2004, Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?, Ann. Rheum. Dis.
Pinto et al., 1996, Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells., Clin. Cancer Res.
Lecomte et al., 2000, Maurotoxin and the Kv1.1 channel: voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys31-Cys34., J. Pept. Res.
Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
Dervieux T et al., 2009, Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis., Pharmacogenet Genomics
Imanishi et al., 2007, Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma., J. Hum. Genet.
López-Rodríguez R et al., 2018, Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis., Sci Rep
Lima A et al., 2015, Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci
Warren RB et al., 2008, Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis., J Invest Dermatol
Yang JJ et al., 2009, Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia., JAMA
Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
Plant D et al., 2012, A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register., Pharmacogenomics J
Hider SL et al., 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX., Rheumatology (Oxford)
Xian et al., 2000, Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis., Br. J. Cancer
Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol
Liu SG et al., 2017, Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia., Oncotarget
Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
Goričar K et al., 2014, Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma., Pharmacogenet Genomics
Csordas K et al., 2014, Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia., Br J Haematol
Ramsey LB et al., 2013, Genome-wide study of methotrexate clearance replicates SLCO1B1., Blood
Treviño LR et al., 2009, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects., J Clin Oncol
Tirona RG et al., 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans., J Biol Chem
Chen et al., 2006, Nuclear receptor interactions in methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1)., J. Biochem. Mol. Toxicol.
Majorczyk E et al., 2014, Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment., BMC Musculoskelet Disord
Kohli et al., 1990, Expression and amplification of cloned rat liver tyrosine aminotransferase in nonhepatic cells., J. Cell. Physiol.
Lora et al., 2004, Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells., Eur. J. Biochem.
Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
Kooloos WM et al., 2010, Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis., Pharmacogenomics
Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.
Krajinovic M et al., 2005, Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL., Pharmacogenomics
Baggott et al., 1986, Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide., Biochem. J.
Stamp LK et al., 2009, Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis., Ann Rheum Dis
Rizzo R et al., 2006, HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis., Pharmacogenet Genomics
Barbisan F et al., 2014, Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism., PLoS One
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Morita et al., The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production., Scand. J. Rheumatol.
Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.
Yazici et al., 2005, The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment., Arch. Dermatol. Res.
Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.
Hall et al., Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells., Int. J. Immunopharmacol.
Seitz et al., 1996, Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate., J. Rheumatol.
Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
Abida et al., 2002, Receptor-dependence of the transcription read-out in a small-molecule three-hybrid system., Chembiochem
Nakagawa H et al., 2008, Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2., Biochem J

METHOTREXATE SLC19A1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

METHOTREXATE ATIC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Allegra et al., 1985, Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates., Proc. Natl. Acad. Sci. U.S.A.

López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J

Kurzawski M et al., 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients., Pharmacogenomics

METHOTREXATE TYMS

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood

Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet

METHOTREXATE DHFR

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name VIBEX MTX

Specific Action of the Ligand Inhibition

Publications:

Kodidela S et al., 2015, Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia., Eur J Clin Pharmacol

Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J

Salazar J et al., 2014, Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?, Pharmacogenomics

METHOTREXATE NOTCH1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
METHOTREXATE RB1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
METHOTREXATE FLT3

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

Publications:

Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
METHOTREXATE BAX

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
METHOTREXATE ADORA2A-AS1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

METHOTREXATE CCND1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Costea I et al., 2006, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia., Haematologica

Costea et al., 2003, The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia., Pharmacogenetics

METHOTREXATE PYGL

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood
METHOTREXATE PTPRM

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics
METHOTREXATE CYP3A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

METHOTREXATE ABCC4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

den Hoed MA et al., 2015, Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia., Pharmacogenomics J

METHOTREXATE SLC46A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
METHOTREXATE TPM3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer
METHOTREXATE PACSIN2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet
METHOTREXATE AFP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.

METHOTREXATE GGH

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Jekic B et al., 2013, Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients., Eur J Clin Pharmacol

Hayashi H et al., 2009, Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis., J Clin Pharm Ther

van der Straaten RJ et al., 2007, Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients., Pharmacogenomics

METHOTREXATE KLRD1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
METHOTREXATE UGT1A7

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE UGT1A8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE HSPB2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids

METHOTREXATE ENOSF1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol

Krajinovic M et al., 2005, Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis., Pharmacogenomics J

METHOTREXATE BIRC5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

METHOTREXATE ABCC3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One

Ansari M et al., 2012, Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia., Pharmacogenomics J

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics

METHOTREXATE FOXP3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol

METHOTREXATE SHMT1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics

Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics

Huang L et al., 2008, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia., Leukemia

METHOTREXATE ABCC2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

METHOTREXATE S100A12

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.

METHOTREXATE AMPD1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J

Chen Y et al., 2017, Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis., Pharmacogenomics

Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J

METHOTREXATE DOK5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
METHOTREXATE TP53

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther

METHOTREXATE CDKN1B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Pohl et al., 2003, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin., J. Clin. Oncol.

METHOTREXATE UGT1A6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE S100A8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Foell et al., 2004, Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?, Ann. Rheum. Dis.
METHOTREXATE UGT1A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

METHOTREXATE FOLH1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Pinto et al., 1996, Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells., Clin. Cancer Res.

Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics

METHOTREXATE UGT1A3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE SLC22A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
METHOTREXATE KCNA1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lecomte et al., 2000, Maurotoxin and the Kv1.1 channel: voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys31-Cys34., J. Pept. Res.

METHOTREXATE ITPA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J

Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J

Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics

METHOTREXATE BMP7

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
METHOTREXATE GSTM1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Imanishi et al., 2007, Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma., J. Hum. Genet.

METHOTREXATE ABCC1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-Rodríguez R et al., 2018, Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis., Sci Rep

Lima A et al., 2015, Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics

METHOTREXATE NALCN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Yang JJ et al., 2009, Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia., JAMA

METHOTREXATE TNFAIP3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Plant D et al., 2012, A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register., Pharmacogenomics J

METHOTREXATE ADORA2A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

Hider SL et al., 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX., Rheumatology (Oxford)

METHOTREXATE HGF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Xian et al., 2000, Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis., Br. J. Cancer

METHOTREXATE SLCO1B1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood

Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol

Liu SG et al., 2017, Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia., Oncotarget

METHOTREXATE FPGS

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sharma S et al., 2009, Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians., Pharmacogenet Genomics
METHOTREXATE SULT2A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Chen et al., 2006, Nuclear receptor interactions in methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1)., J. Biochem. Mol. Toxicol.
METHOTREXATE SLCO1B3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
METHOTREXATE HLA-C

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol
METHOTREXATE SLC22A11

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lima A et al., 2015, Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci
METHOTREXATE KIR2DS4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Majorczyk E et al., 2014, Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment., BMC Musculoskelet Disord
METHOTREXATE SLCO1A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
METHOTREXATE FOLR1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
METHOTREXATE TAT

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kohli et al., 1990, Expression and amplification of cloned rat liver tyrosine aminotransferase in nonhepatic cells., J. Cell. Physiol.
METHOTREXATE GLS

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lora et al., 2004, Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells., Eur. J. Biochem.

METHOTREXATE ATP5F1E

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol

METHOTREXATE TLR4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kooloos WM et al., 2010, Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis., Pharmacogenomics
METHOTREXATE CYP2C19

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
METHOTREXATE FGFR4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
METHOTREXATE NTRK1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer
METHOTREXATE DROSHA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
METHOTREXATE GATA3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
METHOTREXATE FCGR3B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.

METHOTREXATE MTRR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-Rodríguez R et al., 2018, Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis., Sci Rep

Huang L et al., 2008, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia., Leukemia

Krajinovic M et al., 2005, Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL., Pharmacogenomics

METHOTREXATE CYP2D6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
METHOTREXATE CYP1A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
METHOTREXATE UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

METHOTREXATE ADA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Baggott et al., 1986, Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide., Biochem. J.

METHOTREXATE HLA-G

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Stamp LK et al., 2009, Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis., Ann Rheum Dis

Rizzo R et al., 2006, HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis., Pharmacogenet Genomics

METHOTREXATE LINC00251

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
METHOTREXATE SOD2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Barbisan F et al., 2014, Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism., PLoS One
METHOTREXATE UGT1A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

METHOTREXATE NOS3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One

Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res

METHOTREXATE ARID5B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Csordas K et al., 2014, Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia., Br J Haematol

METHOTREXATE SLAMF1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Morita et al., The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production., Scand. J. Rheumatol.

METHOTREXATE E2F1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.

METHOTREXATE CYP2C9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
METHOTREXATE ICAM3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Yazici et al., 2005, The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment., Arch. Dermatol. Res.
METHOTREXATE SPECC1L

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hider SL et al., 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX., Rheumatology (Oxford)
METHOTREXATE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.

METHOTREXATE IL2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hall et al., Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells., Int. J. Immunopharmacol.

METHOTREXATE IL1RN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Seitz et al., 1996, Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate., J. Rheumatol.

METHOTREXATE UGT1A5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE UGT1A10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
METHOTREXATE SLC22A8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
METHOTREXATE NR3C1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Abida et al., 2002, Receptor-dependence of the transcription read-out in a small-molecule three-hybrid system., Chembiochem

METHOTREXATE ABCG2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J

Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J

METHOTREXATE POLH

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE VDR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE IDH1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE HSD17B10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE SLC16A7

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE NCOA3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE PPARG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE HLA-E

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE MPHOSPH8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE EHMT2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE NFE2L2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE TARDBP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE POLB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE APEX1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
METHOTREXATE POLI

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00563

Version: 5.1.7

Alternate Names:

METHOTREXATE DrugBank Drug Name

59-05-2 CAS Number

Abitrexate Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories abortifacient agents

Publications:

Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet

Al-Rashood et al., 2006, Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs., Bioorg. Med. Chem.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

TdgClinicalTrial: METHOTREXATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications DMARD

Drug Class Small molecule

FDA Approval approved

Publications:

NCI: METHOTREXATE

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer

Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.

Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer

NCI: MTX

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.

Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.

NCI: AMETHOPTERIN

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry

DTC: METHOTREXATE
- Version: 02-September-2020
Alternate Names:

CHEMBL34259 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: methotrexate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics

Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

JAX-CKB: Methotrexate

Version: 15-September-2020

Alternate Names:

Drug Info:

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

TTD: Methotrexate
- Version: 2020.06.01
Alternate Names:

D0SV8E TTD Drug ID

Drug Info:

Publications:
GuideToPharmacologyInteractions: 178101517
- Version: 20-July-2020
Alternate Names:

METHOTREXATE GuideToPharmacology Ligand Name

Drug Info:

Publications:
DTC: TCMDC-125488
- Version: 02-September-2020
Alternate Names:

CHEMBL426 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL34259
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL34259
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Novel drug target	Established target
Trial Name	VIBEX MTX
Specific Action of the Ligand	Inhibition

combination therapy	Ribociclib + Methotrexate
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	decreased response

combination therapy	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin
Indication/Tumor Type	acute promyelocytic leukemia
Response Type	sensitive

METHOTREXATE	DrugBank Drug Name
59-05-2	CAS Number
Abitrexate	Drug Brand

METHOTREXATE Drug Record

METHOTREXATE chembl:CHEMBL34259 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name VIBEX MTX Specific Action of the Ligand Inhibition

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Methotrexate Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type decreased response

Publications: Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Methotrexate Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type decreased response

Publications: Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin Indication/Tumor Type acute promyelocytic leukemia Response Type sensitive

Publications: Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name VIBEX MTX

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

Publications:

Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

Interaction Types & Directionality:

n/a

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer

Interaction Types & Directionality:

n/a

Publications:

Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood

Interaction Types & Directionality:

n/a

Publications:

Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer

Interaction Types & Directionality:

n/a

Publications:

Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet

Interaction Types & Directionality:

n/a

Publications:

Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

Interaction Types & Directionality:

n/a

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Interaction Types & Directionality:

n/a

Publications:

Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther

Interaction Types & Directionality:

n/a

Publications:

Pohl et al., 2003, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin., J. Clin. Oncol.

Interaction Types & Directionality:

n/a

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Foell et al., 2004, Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?, Ann. Rheum. Dis.